Zyrtec driving sales and earnings at UCB
Belgian chemicals and pharmaceutical firm UCB has reported a 19%increase in group sales at 2.48 billion euros ($2.16 billion) for full-year 2001, and pretax profits of 461 million euros, up 25%.
Pharmaceutical turnover for the group reached 1.43 billion euros for the period, a rise of 24%, while ordinary profits for the segment jumped 47% to 402 million euros. The increases were due largely to the progress made by the anti-allergy drug Zyrtec (cetirizine), total sales of which reached more than 1.7 billion euros. In the USA, where the drug is marketed by Pfizer, revenues rose 44.1% to over 1.1 billion euros, while, in Japan, Zyrtec turnover grew 10% to 207 million euros.
Drug to go OTC?
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze